Literature DB >> 31954727

Jak Inhibition Prevents Bleomycin-Induced Fibrosis in Mice and Is Effective in Patients with Morphea.

William Damsky1, Dhrumil Patel2, Colton J Garelli2, Madhuri Garg2, Alice Wang1, Karen Dresser3, April Deng3, John E Harris2, Jillian Richmond2, Brett King4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31954727     DOI： 10.1016/j.jid.2019.12.019

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  5 in total

Review 1.  New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.

Authors:  Alain Lescoat; John Varga; Marco Matucci-Cerinic; Dinesh Khanna
Journal:  Expert Opin Investig Drugs       Date:  2021-05-13       Impact factor: 6.498

Review 2.  Morphea: progress to date and the road ahead.

Authors:  Laila Abbas; Adrienne Joseph; Elaine Kunzler; Heidi T Jacobe
Journal:  Ann Transl Med       Date:  2021-03

3.  JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis.

Authors:  Zhanying Hou; Xuehan Su; Guangming Han; Ruzeng Xue; Yangxia Chen; Ye Chen; Huan Wang; Bin Yang; Yunsheng Liang; Suyun Ji
Journal:  Front Med (Lausanne)       Date:  2022-06-06

4.  Potential therapeutic manipulations of the CXCR3 chemokine axis for the treatment of inflammatory fibrosing diseases.

Authors:  Morgan K Groover; Jillian M Richmond
Journal:  F1000Res       Date:  2020-10-05

Review 5.  Upcoming treatments for morphea.

Authors:  Dan Wenzel; Nazgol-Sadat Haddadi; Khashayar Afshari; Jillian M Richmond; Mehdi Rashighi
Journal:  Immun Inflamm Dis       Date:  2021-07-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.